COMMUNIQUÉS West-GlobeNewswire

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/10/2025
BRISBANE, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today [...]
BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting
03/10/2025
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company [...]
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/10/2025
SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of [...]
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
03/10/2025
Initial closing of approximately $81 million expected to fund current operating plan and clinical pipeline into 2028, with potential for up to $94 million in additional proceeds upon exercise of issued warrants NEW YORK [...]
Cartesian Therapeutics Announces New Employment Inducement Grant
03/10/2025
FREDERICK, Md., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the [...]
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/10/2025
RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted eight newly-hired [...]
Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile
03/10/2025
An expansive biomarker study confirmed OV329 delivered statistically significant inhibition of GABA-AT as measured across multiple metrics OV329 matched or exceeded inhibition demonstrated by therapeutic doses of first- [...]
Angelini Ventures Leads €12 Million Follow-On Investment in Serenis, a Fast-Growing Digital Mental and Physical Health Company
03/10/2025
Through its investment, Angelini Ventures aims to promote the expansion and acceleration of Serenis’ digital health and wellbeing services and amplify its leadership in delivering transformative solutions to corporate [...]
Nomination de Marc Le Bozec comme Directeur Général par interim
03/10/2025
Nomination de Marc Le Bozec comme Directeur Général par interim NANTES, France, 3 octobre 2025, 8 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), annonce la cessation des fonctions de M. Nicolas [...]
Appointment of Marc Le Bozec as Interim CEO
03/10/2025
Appointment of Marc Le Bozec as Interim CEO Nantes, October 3, 2025, 8:00 a.m. CET – OSE Immunotherapeutics (ISIN: FR0012127173; Mnemonic: OSE) announces the termination of the position as chief executive officer of Mr [...]
FDA approves Roche’s Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer
03/10/2025
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study 1 First and only combination therapy for the first-line maintenance treatment of ES-SCLC, [...]
Santhera Announces Approval in Canada for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
03/10/2025
Health Canada approved AGAMREE for the treatment of Duchenne muscular dystrophy in patients aged 4 years and older This approval makes AGAMREE the first and only approved therapy for DMD in Canada Pratteln, Switzerland [...]
Change in the Roche Board of Directors
03/10/2025
Basel, 3 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Dr. Claudia Süssmuth Dyckerhoff has decided not to stand for re-election as a member of the Roche Board of Directors at the Annual General [...]
Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access
03/10/2025
NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that a specific Healthcare Common Procedure [...]
Vireo Growth Inc. Enters into Definitive Agreements to Acquire Outstanding Senior Secured Convertible Notes of Schwazze
03/10/2025
– Transaction reflects continuation of Vireo’s M&A strategy and is expected to close later this month – MINNEAPOLIS, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: [...]
CORRECTION – Algae-C Acquisition by Rockcliffe Labs
02/10/2025
TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Algae-C Inc. (“Algae-C”) today issues a correction to its earlier release announcing its acquisition by Rockcliffe Labs Inc. (“Rockcliffe Labs”). The prior release suggested [...]
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
02/10/2025
EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) and LAVA Therapeutics N.V. (“LAVA”) (Nasdaq: LVTX) today [...]
BEYOND IMMORTALITY: European Wellness Biomedical Group Unveils Landmark Research on Longevity Through Cell Regeneration Over Organ Transplants
02/10/2025
From hot-mic whispers of World Leaders to groundbreaking science, Prof. Mike Chan reveals why cellular regeneration — not organ swaps, holds the key to extending human healthspan and lifespan. A Whisper in Beijing [...]
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/10/2025
WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living [...]

Pages